PUBLISHER: GlobalData | PRODUCT CODE: 1384462
PUBLISHER: GlobalData | PRODUCT CODE: 1384462
The report provides an in-depth assessment of the Myasthenia gravis market including disease overview, epidemiology, current treatment options, unmet needs and opportunities, R&D strategies, pipeline assessment, and market outlook.
Myasthenia Gravis (MG) is an autoimmune and neuromuscular disease that is characterized by muscle weakness and fatigue. In the majority of patients, the disease is initially localized and limited to the eye muscles, causing drooping of the eyelid (ptosis) and double vision (diplopia). This weakness can give patients difficulty controlling eye and eyelid movement, facial expressions, chewing, and talking. In some cases, the disease progressively begins to affect respiratory muscles. MG is considered to be the most common neuromuscular disorder, although it is still classified as a rare disease. The precise etiology of MG is idiopathic, and while factors such as infections are known to increase susceptibility, the specific cause is often indeterminable. The disruption of the normal communication between nerves and muscles at the neuromuscular junction is a key pathological process in MG, which results in impairment of the patient's ability to engage in voluntary muscle movements.
Report deliverables include a Pdf and an Excel-based forecast model
Forecast includes the 7 major markets (7MM)
Forecast covers the period 2022-2032